OLI 03 2005 E

ITW

, 2000 w				Approved for us	PTO/SB/21 (09-04) e through 07/31/2006. OMB 0651-0031	
1005 gr	ork Reduction Act of 1995, no	U.S. persons are required to respond to a control Application Number	Patent and T ollection of inf	rademark Office	U.S. DEPARTMENT OF COMMERCE it displays a valid OMB control number.	
(aleger			10/785,16	9		
TRANSMITTAL FORM (to be used for all correspondence after initial filing) Total Number of Pages in This Submission 10		Filing Date	February 2	February 23, 2004		
		First Named Inventor	KARL, Mit	KARL, Mitchell S.		
		Art Unit	1615	1615		
		Examiner Name	Eric E. Silv	Eric E. Silverman		
		Attorney Docket Number	43069-000	43069-0003		
ENCLOSURES (Check all that apply)						
Fee Transmitt	al Form	Drawing(s)			Allowance Communication to TC	
	ttached	Licensing-related Papers		of Ar	peals and Interferences	
Zi Amendmente		Petition			al Communication to TC eal Notice, Brief, Reply Brief)	
		Petition to Convert to a Provisional Application	Petition to Convert to a		rietary Information	
		Power of Attorney, Revocation	Power of Attorney, Revocation		s Letter	
			Change of Correspondence Address		r Enclosure(s) (please Identify	
Extension of Time Request		Terminal Disclaimer	Po		v): eipt Postcard	
Express Aban	donment Request	Request for Refund	Request for Refund		eipt Fostcard	
Information Disclosure Statement		CD, Number of CD(s)	CD, Number of CD(s)			
Landscape Table on CD						
Certified Copy	of Priority	Remarks			······································	
Document(s)						
Reply to Missing Parts/ Incomplete Application						
Reply to Missing Parts under 37 CFR 1.52 or 1.53						
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm Name Ruden, McClosky, Smith, Schuster & Russell, P.A.						
Signature (UC) AA						
Printed name Amy A. Ostrom, Ph.D.						
Date September 29, 2005			Reg. No. 52,088			
CERTIFICATE OF TRANSMISSION/MAILING						
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:						
Signature M A A						
Typed or printed name Amy A. Ostrom, Pl).		Date	September 29, 2005	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of KARL, Mitchell S.

Application No.:

10/785,169

Examiner:

Silverman, Eric E.

Date filed:

February 23, 2004

Group:

1615

For:

PREPACKAGED AQUEOUS PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF CARDIAC CONDITIONS CONTAINING AT LEAST TWO DIFFERENT ACTIVE AGENTS AND METHOD OF FORMULATION

CERTIFICATE UNDER 37 CFR 1.8(A)

I hereby certify that this correspondence is being deposited with the United States Postal Service for delivery to the United States

Patent and Tradenfark Office on

, Reg. No. 52,088

Amy A. Ostrom, Ph.D.

RESPONSE UNDER 37 C.F.R. §1.111

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the office action mailed June 29, 2005, (hereinafter the "Office Action"), please enter the amendments and consider the remarks as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks/Arguments begin on page 7 of this paper.